Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 609-256-3 | CAS number: 365400-11-9
Toxicological information
Skin sensitisation
Currently viewing:
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 06 Apr - 14 Jun 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Version / remarks:
- adopted 17 Jul 1992
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- The study was conducted prior to the current requirement in Regulation (EC) 1907/2006 to perform an LLNA study (OECD 429) as the preferred in vivo skin sensitisation study.
Test material
- Reference substance name:
- 4-[2-methanesulfonyl-4-(trifluoromethyl)benzoyl]-1,3-dimethyl-1H-pyrazol-5-ol
- EC Number:
- 609-256-3
- Cas Number:
- 365400-11-9
- Molecular formula:
- C14H13F3N2O4S
- IUPAC Name:
- 4-[2-methanesulfonyl-4-(trifluoromethyl)benzoyl]-1,3-dimethyl-1H-pyrazol-5-ol
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- other: Crl:HA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratory Animal Breeders, Kisslegg, Germany
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 5 - 6 weeks
- Weight at study initiation: 296 - 393 g
- Housing: 5 animals (acclimation period) or 2 - 3 animals (study period) in type IV Makrolon® cages with low-dust wood shavings bedding (Rettenmeier & Söhne GmbH & Co., Rosenberg, Germany)
- Diet: Provimi Kliba 3420 - Maintenance Diet for Guinea Pigs, Provimi Kliba AG, ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 40 - 70%
- Air changes (per hr): ≥ 10
- Photoperiod (hrs dark / hrs light): 12/12
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal
- Vehicle:
- physiological saline
- Concentration / amount:
- 5% (40 mg/animal)
- Day(s)/duration:
- single injection
- Adequacy of induction:
- other: highest concentration used in a dose-range-finding study for intradermal induction leading to wheal after 24 and 48 h in the test animal
- Route:
- epicutaneous, occlusive
- Vehicle:
- physiological saline
- Concentration / amount:
- 6% (30 mg/animal)
- Day(s)/duration:
- 48 h
- Adequacy of induction:
- other: concentration used in a dose-range-finding study and induced slight localized redness after 48 h in 3/4 animals
Challenge
- No.:
- #1
- Route:
- epicutaneous, occlusive
- Vehicle:
- physiological saline
- Concentration / amount:
- 3% (15 mg/animal)
- Day(s)/duration:
- 24 h
- Adequacy of challenge:
- other: highest concentration used in a dose-range-finding study for challenge which was non-irritant
- No. of animals per dose:
- Range-finding study: 1 (intradermal induction), 4 (topical induction), 2 (challenge)
Main study: 10 (controls), 20 (test group) - Details on study design:
- RANGE FINDING TESTS:
For the dose range-finding for intradermal induction one animal was given intradermal injections with 0.1 mL of 0, 1, 2.5 and 5% test substance in physiological saline. The evaluation of the injection sites 24 and 48 h showed no effect at the 0% site but wheal at all other sites. Thus, 5% of the test substance was selected for the intradermal induction. For topical induction two studies with four animals each and three concentration (0, 12, 25 and 50% in the first study and 0, 1, 3 and 6% in the second study respectively) were conducted. The skin reactions were evaluated 48 and 72 h after start of application and based on the findings 6% of the test substance was selected for epicutaneous induction. Two animals were administered three concentrations of the test substance (0, 0.5, 1 and 3%) under occlusive conditions for 24 h for the dose range-finding for challenge. The skin reactions were evaluated 48 and 72 h after start of application and based on the findings 3% of the test substance was selected for challenge.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal and epicutaneous, respectively)
- Exposure period: single injection (intradermal) and 48 h (epicutaneous)
- Test groups:
Injection 1: a 1:1 mixture FCA/physiological saline solution
Injection 2: 5% test substance in physiological saline solution
Injection 3: equal amounts of 5% test substance in physiological saline solution and FCA
Epicutaneous: 0.5 mL 6% test substance in physiological saline solution
- Control group:
Injection 1: a 1:1 mixture FCA/physiological saline solution
Injection 2: undiluted physiological saline solution
Injection 3: a 1:1 mixture FCA/physiological saline solution
Epicutaneous: 0.5 mL physiological saline solution
- Site: cranial/bilateral (injection 1 and 3), medial/bilateral (injection 2)
- Frequency of applications: single injection (intradermal), single application (epicutaneous induction; one week after intradermal application)
- Duration: 9 days
- Concentrations: intradermal induction 5%, epicutaneous 6%
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: three weeks after intradermal induction (day 21)
- Exposure period: 24 h
- Test groups: 3% test substance in physiological saline solution
- Control group: 3% test substance in physiological saline solution
- Site: right flank (caudal)
- Concentrations: 3%
- Evaluation (hr after challenge): 48 and 72 h after the start of the application to induce the challenge (24 and 48 h after patch removal)
OTHER:
- Clinical signs: The animals were observed for clinical signs at least once daily throughout the entire study period.
- Body weights: The body weights of the animals were recorded before the first induction and at the end of the study. - Challenge controls:
- The control group is actually a challenge control.
- Positive control substance(s):
- yes
- Remarks:
- (alpha hexyl cinnamic aldehyde formulated in polyethylene glycol 400; intradermal induction: 5%, epicutaneous induction: 25%, challenge: 12%)
Results and discussion
- Positive control results:
- 100% of the test animals exhibited dermal reactions in the challenge treatment with the positive control substance. There was no reddening of the skin to be observed on control group animals.
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- Induction: 0%; challenge: 3%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- strong effects up to encrustation at the injection sites after intradermal induction
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- Induction: 5% (intradermal) and 6% (epicutaneous); challenge: 3%
- No. with + reactions:
- 0
- Total no. in group:
- 19
- Clinical observations:
- strong effects up to encrustation at the injection sites after intradermal induction; clinical signs (poor general condition, piloerection, laboured breathing, pale) and subsequent death (day 15) in 1/20 animal
- Remarks on result:
- no indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- Induction: 0%, challenge: 3%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- strong effects up to encrustation at the injection sites after intradermal induction
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- Induction: 5% (intradermal) and 6% (epicutaneous), challenge: 3%
- No. with + reactions:
- 0
- Total no. in group:
- 19
- Clinical observations:
- strong effects up to encrustation at the injection sites after intradermal induction; clinical signs (poor general condition, piloerection, laboured breathing, pale) and subsequent death (day 15) in 1/20 animal
- Remarks on result:
- no indication of skin sensitisation
- Reading:
- 1st reading
- Group:
- positive control
- Dose level:
- Induction: 5% (intradermal) and 25% (epicutaneous), challenge: 12%
- Remarks on result:
- positive indication of skin sensitisation
- Remarks:
- 100% of the test animals exhibited dermal reactions in the challenge treatment.
Any other information on results incl. tables
- Body weights:
At the end of the study, the mean body weight of the treatment group animals was in the same range than that of the control group animals.
Applicant's summary and conclusion
- Interpretation of results:
- other: CLP/GHS criteria not met; no classification required according to Regulation (EC) No. 1272/208
- Conclusions:
- The study was performed in accordance to OECD TG 406 under GLP conditions and is considered reliable. The test substance was non-sensitizing.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
